What does the Cerdelga (eliglustat tartrate) product information say about use during breastfeeding?

For Cerdelga (eliglustat tartrate), human milk excretion of metabolites is unknown, animal milk excretion is documented, and infant risk cannot be excluded, so a decision must be made to discontinue breastfeeding or discontinue/avoid treatment, weighing breastfeeding benefits for the child against treatment benefits for the woman.